Advertisement
U.S. markets closed

Outlook Therapeutics, Inc. (OTLK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.78-0.45 (-5.52%)
At close: 04:00PM EDT
7.93 +0.14 (+1.86%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close8.24
Open8.09
Bid0.39 x 800
Ask0.39 x 800
Day's Range7.31 - 8.42
52 Week Range4.00 - 40.60
Volume391,430
Avg. Volume155,035
Market Cap101.305M
Beta (5Y Monthly)-0.00
PE Ratio (TTM)N/A
EPS (TTM)-4.00
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for OTLK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Outlook Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 12/15/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

    ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement, for upfront gross proceeds of approximately $60 million from the issuance and sale of shares of the Company’s common stock and accompanying warrants, before d

  • GlobeNewswire

    Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

    ISELIN, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective on March 14, 2024. The Company’s common stock will begin trading on a reverse stock split-adjusted basis at the opening of the ma

  • InvestorPlace

    7 of the Best Speculative Stocks You Can Snag for Less Than $1

    I’m about to drop a truth bomb about speculative stocks under $1. Back when I was a freshman in college, the on-campus security officer had this to say: “Tijuana? You don’t wanna.” Subsequently, the crowd erupted in laughter but the officer got his point across. Yes, Tijuana is an exciting and vibrant city, no doubt about it. However, people – especially young underage college students – can get carried away. That’s the reality behind speculative stocks under $1. It’s like Tijuana, where the sam